Roche Re-Models Around Disease Areas, Pulls Together R&D And Commercial
Executive Summary
Roche is taking a dual approach in reorganizing its global R&D business by centering on key disease areas and consolidating its full operations, from R&D to marketing, along those lines
You may also be interested in...
Roche Makes Early Headway With Pharmaco-Diagnostics
As discussion of personalized medicine transitions from being a hot new topic to a predominant mentality for R&D, a lot of focus is on Roche to see how the diversified company leverages its dual footholds in the pharmaceutical and diagnostics worlds
Roche Makes Early Headway With Pharmaco-Diagnostics
As discussion of personalized medicine transitions from being a hot new topic to a predominant mentality for R&D, a lot of focus is on Roche to see how the diversified company leverages its dual footholds in the pharmaceutical and diagnostics worlds
Roche Mantra Is “Pipeline, Pipeline, Pipeline;” R&D Surge Continues In 2008
Roche spending increases on pharmaceutical research and development will continue to outpace sales gains in 2008, company executives said during the firm's fourth quarter financial review Jan. 30